PARP1 and breast cancer: Targeted treatments, including mAbs, TKIs, ADCs, PI3K/Akt/mTOR pathway inhibitors, CDK4/6 inhibitors, PARP inhibitors, EGFR inhibitors and antiangiogenic agents have reshaped BC treatment paradigms.